NWBO Northwest Biotherapeutics Inc

Price (delayed)

$0.4

Market cap

$483.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$529.87M

Highlights
NWBO's net income is up by 31% year-on-year but it is down by 12% since the previous quarter
Northwest Biotherapeutics's quick ratio has plunged by 71% YoY and by 20% from the previous quarter
NWBO's debt has soared by 56% YoY and by 8% QoQ

Key stats

What are the main financial stats of NWBO
Market
Shares outstanding
1.21B
Market cap
$483.27M
Enterprise value
$529.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
355.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
396.61
Earnings
Revenue
$1.34M
EBIT
-$64.53M
EBITDA
-$62.69M
Free cash flow
-$57.15M
Per share
EPS
-$0.07
Free cash flow per share
-$0.05
Book value per share
-$0.06
Revenue per share
$0
TBVPS
$0.02
Balance sheet
Total assets
$28.57M
Total liabilities
$82.04M
Debt
$49.08M
Equity
-$73.28M
Working capital
-$57.49M
Liquidity
Debt to equity
-0.67
Current ratio
0.08
Quick ratio
0.04
Net debt/EBITDA
-0.74
Margins
EBITDA margin
-4,692.4%
Gross margin
100%
Net margin
-5,258.9%
Operating margin
-4,362.9%
Efficiency
Return on assets
-248.2%
Return on equity
N/A
Return on invested capital
-412.3%
Return on capital employed
N/A
Return on sales
-4,829.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NWBO stock price

How has the Northwest Biotherapeutics stock price performed over time
Intraday
2.56%
1 week
-6.98%
1 month
-6.98%
1 year
-29.68%
YTD
-42.94%
QTD
-6.98%

Financial performance

How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.34M
Gross profit
$1.34M
Operating income
-$58.29M
Net income
-$70.26M
Gross margin
100%
Net margin
-5,258.9%
NWBO's net margin has shrunk by 62% QoQ and by 12% YoY
NWBO's operating margin has dropped by 52% since the previous quarter and by 39% year-on-year
Northwest Biotherapeutics's revenue has decreased by 38% YoY and by 31% QoQ
The company's gross profit fell by 38% YoY and by 31% QoQ

Growth

What is Northwest Biotherapeutics's growth rate over time

Valuation

What is Northwest Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
355.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
396.61
The EPS has contracted by 17% from the previous quarter
The equity has contracted by 31% YoY and by 11% from the previous quarter
Northwest Biotherapeutics's revenue has decreased by 38% YoY and by 31% QoQ
The P/S is 28% below the 5-year quarterly average of 492.0 and 16% below the last 4 quarters average of 424.3

Efficiency

How efficient is Northwest Biotherapeutics business performance
The ROS has plunged by 63% from the previous quarter and by 8% YoY
The return on assets rose by 25% year-on-year but it has declined by 16% since the previous quarter
The ROIC has decreased by 14% QoQ

Dividends

What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NWBO.

Financial health

How did Northwest Biotherapeutics financials performed over time
The total assets is 65% smaller than the total liabilities
Northwest Biotherapeutics's quick ratio has plunged by 71% YoY and by 20% from the previous quarter
The current ratio has dropped by 62% year-on-year and by 11% since the previous quarter
NWBO's debt is 167% higher than its equity
NWBO's debt has soared by 56% YoY and by 8% QoQ
The equity has contracted by 31% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.